Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets
June 25, 2025 4:05 PM EDTBrookline Capital Markets analyst Leah Rush Cann lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $70.00 (from $97.00) while maintaining a Buy rating.
The analyst comments "Conclusions Our estimated revenue for 2025 2027 is being reduced resulting from timing of collaboration revenue from Sanofi. We have... More
Stifel says buy Kymera Therapeutics (KYMR) on today's weakness
June 25, 2025 10:32 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR), saying they would buy on today's weaknesses related to the updated on the Sanofi IRAK4 collaboration. Shares of KYMR are down 3.7% currently.
The analyst commented, "We are reiterating our Buy Rating on... More
Leerink Partners Reiterates Outperform Rating on Kymera Therapeutics (KYMR)
June 25, 2025 9:21 AM EDTLeerink Partners analyst Faisal Khurshid reiterated an Outperform rating and $60.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "KYMR announced two pipeline updates this morning: (1) SAN FP (OP, Risinger) has decided not to advance their partnered Ph 2-stage IRAK4 degrader KT-474 and will instead advance a next-gen candidate KT-485 based on an improved pre-clinical profile, and (2) KYMR and GILD (OP, Graybosch) have... More
Kymera Therapeutics (KYMR) Announces Sanofi IRAK4 Collaboration Update
June 25, 2025 7:05 AM EDTKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partnership with Sanofi.
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to... More
Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025 7:02 AM EDTGilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.
CDK2-directed MGDs are a new type of drug designed to remove CDK2 a key contributor in tumor growth rather than just inhibiting its function. Traditional inhibitors of CDK2 prevent it from working... More
